Acotec Scientific Holdings Limited (ACOTEC-B) aktie

Acotec Scientific Holdings Limited operates as an interventional medical device company that offers vascular interventional treatment products in Mainland China and internationally. The company's products include AcoArt Orchid & Dhalia, a paclitaxel DCB used to prevent stenosis or occlusion in superficial femoral artery and popliteal artery for the treatment of lower extremity artery disease with a vascular interventional approach; and AcoArt Tulip & Litos, a paclitaxel coated DCB used to prevent stenosis or occlusion in below-theknee arteries for the treatment of chronic limb-threatening ischemia with a vascular interventional approach. It also offers devices for vascular surgery, including AcoArt Iris & Jasmin; AcoArt Lily & Rosmarin; peripheral aspiration system; radiofrequency ablation system; peripheral support catheter; The PTA balloon; 2nd gen peripheral aspiration system; introducer sheath set; and the delivery catheter for aspiration catheter. In addition, it offers cardiology devices, including semi-compliant PTCA balloon; coronary CTO recanalization balloon; coronary CTO antegrade micro-catheter; coronary high-pressure balloon; cardiac valve balloon dilation catheter; AcoArt Camellia; and coronary micro-catheter. Further, the company provides nephrology devices, such as paclitaxel coated high-pressure balloon and AV scoring balloon; and neurology devices comprising intracranial PTA balloons and vertebral artery paclitaxel-coated balloon dilatation catheter, as well as trades in procedural medical devices. The company was founded in 2011 and is headquartered in Beijing, China. Acotec Scientific Holdings Limited operates as a subsidiary of Boston Scientific Group plc.